All In Biotech

Free tool

FAERS Monitor: Xenpozyme

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761261 or its brand name (Xenpozyme, Olipudase Alfa-Rpcp). Reports on generic versions are filed under their own applications.

Reports

137

Serious

32

23% of reports

Hospitalization

21

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • headache10
  • incorrect dose administered10
  • weight increased10
  • fatigue9
  • nausea7
  • off label use6
  • vomiting6
  • aspartate aminotransferase increased5
  • condition aggravated5
  • erythema5
  • illness5
  • pyrexia5
  • sinusitis5
  • weight decreased5
  • alanine aminotransferase increased4

Reports by year received

View as table
YearReports
20223
202339
202435
202529
202631

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,022 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
aspartate aminotransferase increasedSignal514.56.150
alanine aminotransferase increasedSignal410.03.824
sinusitisSignal57.53.222
illnessSignal57.53.222
weight increasedSignal106.93.845
incorrect dose administeredSignal106.73.744
erythemaSignal53.71.68
weight decreasedSignal52.71.24
condition aggravated52.51.13
headacheSignal102.41.37
pyrexia52.20.92
vomiting62.00.92
fatigue91.80.92
nausea71.40.70
off label use61.10.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.